Newsletter

Ultragenyx Reports Positive Initial Data on DTX401 Clinical Trial

On May 15, Ultragenyx Pharmaceutical Inc. (RARE) presented positive initial data from all three cohorts in its DTX401 clinical trial. DTX401 is an adeno-associated virus-based gene therapy. It is undergoing clinical trials for the treatment of glycogen storage disease type 1a (GSD1a). All patients demonstrated significant cornstarch reductions over time and increases in time to […]

0Comments

April 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: April Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 92% Avg Increase – Next open to 5-day Peak 9% Other stats: Number of signals over $10/share 9 Number […]

0Comments

Akebia Announces Positive Phase 3 Clinical Trial Results

Akebia Therapeutics, Inc. (AKBA) announced positive top-line results on May 5 for the first of its two Phase 3 cardiovascular outcomes programs. The two INNO2VATE studies evaluated the efficacy and safety of Akebia’s drug vadadustat. The drug treats anemia due to chronic kidney disease in adult patients on kidney dialysis. The studies indicate that the treatment […]

0Comments

March 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: March Scorecard Number of Signals 13 Percent Correct – Prev Close to 5-day Peak 77% Avg Increase – Next open to 5-day Peak 5% Other stats: Number of signals over $10/share 6 Number […]

0Comments

February 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: February Scorecard Number of Signals 13 Percent Correct – Prev Close to 5-day Peak 85% Avg Increase – Next open to 5-day Peak 12% Other stats: Number of signals over $10/share 7 Number […]

0Comments

InflaRx Announces Positive Initial Data from Phase IIa Clinical Trial

On February 26, InflaRx, N.V. (IFRX) announced positive initial data from the first 5 patients enrolled in its Phase IIa open label clinical trial for IFX-1. Two out of the five patients achieved complete remission of Pyoderma Gangraenosum (PG), a rare and debilitating autoinflammatory skin disease. Although the exact prevalence of PG is unknown, current […]

0Comments

January 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: January Scorecard Number of Signals 18 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 11 Number […]

0Comments

December 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: December Scorecard Number of Signals 19 Percent Correct – Prev Close to 5-day Peak 89% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 11 Number […]

0Comments

November 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: November Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 92% Avg Increase – Next open to 5-day Peak 14% Other stats: Number of signals over $10/share 6 Number […]

0Comments

October 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October Scorecard Number of Signals 20 Percent Correct – Prev Close to 5-day Peak 95% Avg Increase – Next open to 5-day Peak 9% Other stats: Number of signals over $10/share 10 Number […]

0Comments